Semaglutide Dose & Dosage: What the Trials and Label Studied
Read this first
This page describes the semaglutide dose and dosage as they appear in published trials and approved labeling — written in the third person, as documented facts. It is not dosing advice and it does not tell anyone what to take. Dosing decisions belong to a prescribing clinician.
In plain terms: semaglutide is started low and raised slowly. The slow climb ("titration") exists for one reason — to let the stomach adjust, because the most common side effects cluster at each step up. It comes two ways: a once-weekly injection under the skin, and a once-daily tablet that has to be taken on an empty stomach. Because the drug lasts about a week in the body, levels stay steady between doses and take roughly five weeks to clear after the last one [13].
Semaglutide dose: the studied escalation schedules
Across the trials and label, the semaglutide dose climbs on a fixed ladder rather than starting at the target. For chronic weight management, the documented subcutaneous schedule is 0.25 mg once weekly for weeks 1-4, then 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg maintenance, stepping up about every four weeks. For type 2 diabetes, the subcutaneous schedule runs 0.25 mg (initiation), then 0.5 mg, then 1.0 mg maintenance, with a 2.0 mg option studied in SUSTAIN FORTE, where 2.0 mg lowered HbA1c more than 1.0 mg [10].
The rationale for the ladder is tolerability, not gradually increasing potency: a pooled analysis found gastrointestinal effects were predominantly mild-to-moderate and concentrated around the titration period [14]. Investigational work has pushed higher still — the STEP UP program studied a 7.2 mg once-weekly subcutaneous dose in obesity.
Semaglutide dosage: injection vs oral routes
The semaglutide dosage differs sharply by route, because the two formulations are absorbed completely differently. The subcutaneous (injection) form is given once weekly. The oral form is a daily tablet co-formulated with an absorption enhancer called SNAC, dosed in the trials as 3 mg daily for 30 days, then 7 mg, then 14 mg — taken on an empty stomach about 30 minutes before the first food, drink, or other oral medicine, with no more than ~120 mL of water. Higher-dose oral obesity programs (OASIS, PIONEER PLUS) studied 25 mg and 50 mg once daily.
The reason oral dosing is so strict is its low oral availability — only about 0.4-1% even with SNAC — which is why fasted administration matters so much [22]. The numbers look very different between routes because they are doing different jobs to land a similar systemic exposure.
Semaglutide injection: route and handling, as studied
The semaglutide injection studied across the SUSTAIN, STEP, SELECT, and FLOW programs is subcutaneous — given under the skin, once weekly [1][2][3][6]. Reported handling, per approved labeling, keeps pre-filled pens refrigerated (2-8 C) before first use, after which they may be kept at room temperature (at or below 30 C) for a defined in-use period (commonly cited as up to 56 days). Reconstituted research preparations are generally kept at 2-8 C and used within about 28 days.
The once-weekly cadence is a direct consequence of the molecule's design: DPP-4 resistance plus albumin binding give it a roughly one-week half-life [13]. None of this is administration guidance for any individual — it is a summary of how the injection was handled and dosed in the cited studies and labeling.
Oral semaglutide: the tablet, decoded
Oral semaglutide solves a hard problem: peptides are normally destroyed in the stomach. The tablet is co-formulated with SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), an absorption enhancer that transiently raises the local stomach pH and helps the intact peptide cross into the bloodstream [22]. Even so, only about 0.4-1% of an oral dose is absorbed, which is why the fasted-stomach rule is non-negotiable in the trials [22].
Clinically, the oral route has its own evidence. PIONEER established oral semaglutide in type 2 diabetes, and higher-dose oral programs extended it toward the weight-management range. A pharmaceutical-sciences review summarizes its half-life and once-daily/once-weekly dosing options across formulations [11]. The takeaway: same molecule, very different delivery math.
Half-life and clearance
Semaglutide's elimination half-life is approximately one week — commonly cited as about 165-168 hours — for both the injection and the tablet, with effectively complete clearance roughly five weeks after the final dose [13]. That long tail is engineered: strong, reversible albumin binding via the C18 fatty di-acid side chain, plus DPP-4 resistance from the Aib-8 substitution [13].
Two practical implications follow directly from that arithmetic, both documented rather than advisory. Steady drug levels persist across the weekly interval, which is what makes once-weekly dosing work. And because clearance takes about five weeks, label guidance advises discontinuing well in advance of a planned pregnancy (commonly cited as roughly two months) [13].